Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study

Stopped early

Conditions studied: Pulmonary Arterial Hypertension, Right-Sided Heart Failure

In brief

Pulmonary arterial hypertension(PAH) is associated with the development of right heart failure. In the setting of heart failure, the heart shifts to increasing dependence on glucose metabolism. In this study, the investigators will perform cardiac positron emission tomography/magnetic resonance imaging (PET/MRI) scans to measure glucose metabolism in the heart before and after initiation of pulmonary vasodilator therapy for pulmonary arterial hypertension.

Key facts

Study ID

NCT04090866

Run by

University of Wisconsin, Madison

People needed

2

Starts

2019-11-14

Expected to finish

2020-07-21

Last updated by the study team

2020-07-27

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• World Health Organization(WHO) group PAH secondary into idiopathic pulmonary arterial hypertension(IPAH) or connective tissue disease associated pulmonary arterial hypertension (CTDPAH)
• New York Heart Association (NYHA) classification I - III heart failure
• Vasodilator therapy naive
• Able to provide informed consent

You may not qualify if…

• Metabolic disorders such as uncontrolled diabetes (A1c > 8%) that may interfere with FDG uptake
• Baseline 6-minute walk distance (6MWD) < 400 feet or NYHA class IV heart failure
• Musculoskeletal abnormalities that would prevent exercise
• Contraindications to MRI

Where it is running

• University of Wisconsin-Madison — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.